Computer-aided detection system developer VuCOMP Inc. has received FDA premarket approval for its film mammography CAD software.
Computer-aided detection system developer VuCOMP Inc. has received FDA premarket approval for its film mammography CAD software. This is the first new mammography CAD system approved by the FDA since 2007, the company said.
M-Vu is indicated for use in screening mammography to identify areas consistent with breast cancer for radiologist review after completing an initial read, according to the company.
In a reader study at the University of North Carolina at Chapel Hill, physicians using the M-Vu CAD system were more effective at reading mammograms and demonstrated a significant increase in the ability to discriminate between cancer and noncancer, according to VuCOMP.
The company will be providing a digital version of the system in the “near future,” VuCOMP president and CEO Jeff Wehnes said in a statement.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.